Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05067933 · ClinicalTrials.gov registry record · Phase 2
A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine
A Phase 2 study, sponsored by Vaxart.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT05067933: Clinical Trial Phase 2 study, sponsored by Vaxart.
NCT05067933 is a Phase 2 study that was terminated before completion, run by Vaxart. The registered enrollment target is 66 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05067933, a Phase 2 study, was terminated before completion, sponsored by Vaxart.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid) vaccine for the prevention of COVID-19. Part 2: This phase will assess the efficacy of prophylactic VXA-CoV2-1.1-S against confirmed COVID-19 occurring from 7 days after second dose with a repeat-dose vaccination schedule in healthy adults compared to placebo. Safety and immunogenicity of VXA-CoV2-1.1-S will also be evaluated in this phase.
Primary Outcome
Solicited symptoms of reactogenicity were predefined systemic signs and symptoms of reactogenicity for which the participant was specifically questioned, and which were noted by the participant in their daily Solicited Symptom Diary for 7 days after each vaccination, including: * fever (any temperature 100°F or higher) * headache * myalgia (muscle pain) * abdominal pain * anorexia (defined and not eating) * nausea * vomiting * diarrhea * malaise/fatigue
Interventions
- OTHER Placebo Tablets
- DRUG VXA-CoV2-1.1-S
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2023-05-09 |
| Phase | Phase 2 |
Why NCT05067933 stopped before completion
NCT05067933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo Tablets is the first listed.
NCT05067933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05067933 about?
NCT05067933 is a clinical study titled "A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine". Part 1: An open label, dose and age escalation phase to evaluate the safety and immunogenicity of VXA-CoV2-1.1-S with a repeat-dose vaccination schedule in healthy adults aged 18 - 75 years old that are either vaccine naive or have received prior vaccination with an mRNA (messenger ribonucleic acid)...
What is the current status of trial NCT05067933?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2021-10-22. Estimated completion is 2023-05-09.
What interventions are being tested in trial NCT05067933?
The interventions under investigation include: Placebo Tablets (OTHER), VXA-CoV2-1.1-S (DRUG).
Who is sponsoring clinical trial NCT05067933?
This trial is sponsored by Vaxart, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05067933's enrollment target sits among peer trials
66 975th of 2000 higher than 1,014 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03067051 · 66 participants · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI